Global Hairy Cell Leukemia Therapeutics Market 2022-2026

Description

List of Tables

Technavio has been monitoring the hairy cell leukemia therapeutics market and it is poised to grow by $ 177.85 mn during 2022-2026, accelerating at a CAGR of 6.7% during the forecast period. Our report on the hairy cell leukemia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing exposure to hazardous substances leading to hairy cell leukemia, growing geriatric population, and strategic alliances.

The hairy cell leukemia therapeutics market analysis includes the product segment and geographic landscape.

Technavio's hairy cell leukemia therapeutics market is segmented as below:

By Product

Chemotherapy
Targeted therapy

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increasing research grants for blood cancers as one of the prime reasons driving the hairy cell leukemia therapeutics market growth during the next few years. Also, advent of novel therapies and special drug designations will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on hairy cell leukemia therapeutics market covers the following areas:

Hairy cell leukemia therapeutics market sizing
Hairy cell leukemia therapeutics market forecast
Hairy cell leukemia therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hairy cell leukemia therapeutics market vendors that include AbbVie Inc., Amgen Inc., Astex Pharmaceuticals Inc., AstraZeneca Plc, Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hikma Pharmaceuticals Plc, Innate Pharma SA, Merck KGaA, Pfizer Inc., and Viatris Inc. Also, the hairy cell leukemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR73600

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Incremental Growth
Exhibit 07: Executive Summary - Data Table on Incremental Growth
Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

5.1 Market segments
Exhibit 24: Chart on Product - Market share 2021-2026 (%)
Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
5.2 Comparison by Product
Exhibit 26: Chart on Comparison by Product
Exhibit 27: Data Table on Comparison by Product
5.3 Chemotherapy - Market size and forecast 2021-2026
Exhibit 28: Chart on Chemotherapy - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on Chemotherapy - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on Chemotherapy - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on Chemotherapy - Year-over-year growth 2021-2026 (%)
5.4 Targeted therapy - Market size and forecast 2021-2026
Exhibit 32: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Product
Exhibit 36: Market opportunity by Product ($ million)

6 Customer Landscape

6.1 Customer landscape overview
Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

7.1 Geographic segmentation
Exhibit 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 40: Chart on Geographic comparison
Exhibit 41: Data Table on Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
7.7 US - Market size and forecast 2021-2026
Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
7.8 Germany - Market size and forecast 2021-2026
Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
7.9 China - Market size and forecast 2021-2026
Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)
7.10 Canada - Market size and forecast 2021-2026
Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
7.11 India - Market size and forecast 2021-2026
Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%)
7.12 Market opportunity By Geographical Landscape
Exhibit 78: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends

8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
Exhibit 79: Impact of drivers and challenges in 2021 and 2026
8.4 Market trends

9 Vendor Landscape

9.1 Overview
9.2 Vendor landscape
Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
9.3 Landscape disruption
Exhibit 81: Overview on factors of disruption
9.4 Industry risks
Exhibit 82: Impact of key risks on business

10 Vendor Analysis

10.1 Vendors covered
Exhibit 83: Vendors covered
10.2 Market positioning of vendors
Exhibit 84: Matrix on vendor position and classification
10.3 AbbVie Inc.
Exhibit 85: AbbVie Inc. - Overview
Exhibit 86: AbbVie Inc. - Product / Service
Exhibit 87: AbbVie Inc. - Key offerings
10.4 Amgen Inc.
Exhibit 88: Amgen Inc. - Overview
Exhibit 89: Amgen Inc. - Product / Service
Exhibit 90: Amgen Inc. - Key offerings
10.5 AstraZeneca Plc
Exhibit 91: AstraZeneca Plc - Overview
Exhibit 92: AstraZeneca Plc - Product / Service
Exhibit 93: AstraZeneca Plc - Key news
Exhibit 94: AstraZeneca Plc - Key offerings
10.6 F. Hoffmann La Roche Ltd.
Exhibit 95: F. Hoffmann La Roche Ltd. - Overview
Exhibit 96: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 97: F. Hoffmann La Roche Ltd. - Key news
Exhibit 98: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 99: F. Hoffmann La Roche Ltd. - Segment focus
10.7 Fresenius SE and Co. KGaA
Exhibit 100: Fresenius SE and Co. KGaA - Overview
Exhibit 101: Fresenius SE and Co. KGaA - Business segments
Exhibit 102: Fresenius SE and Co. KGaA - Key news
Exhibit 103: Fresenius SE and Co. KGaA - Key offerings
Exhibit 104: Fresenius SE and Co. KGaA - Segment focus
10.8 Hikma Pharmaceuticals Plc
Exhibit 105: Hikma Pharmaceuticals Plc - Overview
Exhibit 106: Hikma Pharmaceuticals Plc - Business segments
Exhibit 107: Hikma Pharmaceuticals Plc - Key offerings
Exhibit 108: Hikma Pharmaceuticals Plc - Segment focus
10.9 Innate Pharma SA
Exhibit 109: Innate Pharma SA - Overview
Exhibit 110: Innate Pharma SA - Product / Service
Exhibit 111: Innate Pharma SA - Key offerings
10.10 Merck KGaA
Exhibit 112: Merck KGaA - Overview
Exhibit 113: Merck KGaA - Business segments
Exhibit 114: Merck KGaA - Key news
Exhibit 115: Merck KGaA - Key offerings
Exhibit 116: Merck KGaA - Segment focus
10.11 Pfizer Inc.
Exhibit 117: Pfizer Inc. - Overview
Exhibit 118: Pfizer Inc. - Product / Service
Exhibit 119: Pfizer Inc. - Key news
Exhibit 120: Pfizer Inc. - Key offerings
10.12 Viatris Inc.
Exhibit 121: Viatris Inc. - Overview
Exhibit 122: Viatris Inc. - Business segments
Exhibit 123: Viatris Inc. - Key offerings
Exhibit 124: Viatris Inc. - Segment focus

11 Appendix

11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 125: Inclusions checklist
Exhibit 126: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 127: Currency conversion rates for US$
11.4 Research methodology
Exhibit 128: Research methodology
Exhibit 129: Validation techniques employed for market sizing
Exhibit 130: Information sources
11.5 List of abbreviations
Exhibit 131: List of abbreviations